Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2339145 | 0.99 | HPGD (0.42) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL12608696 | 0.97 | HPGD (0.44) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL14548898 | 0.93 | SIGMAR1 (0.39) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL12608676 | 0.91 | HPGD (0.49) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL12608677 | 0.87 | HPGD (0.47) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL15848965 | 0.85 | HPGD (0.58) | HPGDALDH1A1CNR2HTTKDM4E | |
| SCHEMBL15848967 | 0.84 | CNR2 (0.46) | HPGDALDH1A1CNR2SIGMAR1 | |
| SCHEMBL12608637 | 0.82 | CNR2 (0.51) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL16548465 | 0.82 | KDM4E (0.53) | HPGDALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL13418993 | 0.82 | CNR2 (0.55) | HPGDALDH1A1CNR2KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2294186-B1 | INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE | INCURON INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190082845-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | INCURON, INC. | 2017-06-15 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-9566265-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2017-02-14 | — | — | US | disclosed |
| US-8765738-B2 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2356093-B1 | Carbazole compounds and therapeutic uses of the compounds | INCURON LLC (RU) | 2013-01-09 | — | — | EP | disclosed |
| EP-2356093-B1 | Carbazole compounds and therapeutic uses of the compounds | INCURON LLC (RU) | 2013-01-09 | — | — | EP | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | INCURON, INC. | 2011-12-15 | — | — | US | disclosed |
| EP-2356093-A1 | Carbazole compounds and therapeutic uses of the compounds | INCURON, LLC (RU) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010042445-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | CLEVELAND BIOLABS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042445-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | CLEVELAND BIOLABS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009143290-A2 | INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE | CLEVELAND BIOLABS, INC (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165229-A1 | CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS | MALT1, PAICS, BCL9 | HPGD 212/4885ALDH1A1 633/4885CNR2 558/4885 |
| US-10137109-B2 | Carbazole compounds and therapeutic uses of the compounds | MALT1, PAICS, BCL9 | HPGD 212/4885ALDH1A1 633/4885CNR2 558/4885 |
| US-20110305661-A1 | Carbazole Compounds and Therapeutic Uses of the Compounds | MALT1, PAICS, TPMT | HPGD 208/4885ALDH1A1 589/4885CNR2 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.